

PROJECT TITLE

Targeting chemotherapy-induced cancer diapause: a phase II study of 5-FU, irinotecan, bevacizumab and hydroxychloroquine in advanced colorectal cancer

PRINCIPAL INVESTIGATOR

Dr. Eric Chen – University Health Network



SCIENTIFIC SUMMARY

Colorectal cancer is the third most commonly diagnosed cancer in Canada and is a leading cause of cancer-related death. The usual treatment for patients with advanced disease is palliative chemotherapy, with an average survival of 30 months. Recent research findings indicate that some cancer cells can survive chemotherapy by becoming less active. This Phase II study will investigate whether combining a drug called hydroxychloroquine with standard of care chemotherapy can overcome this resistance and improve patient outcomes.